- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03051789
Cups or Cash for Girls Trial to Reduce Sexual and Reproductive Harm and School Dropout (CCg)
Menstrual Cups and Cash Transfer to Reduce Sexual and Reproductive Harm and School Dropout in Adolescent Schoolgirls in Western Kenya: a Cluster Randomised Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Title: Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls in western Kenya: a cluster randomised controlled trial.
Short Title: Cups or cash for girls (CCg) trial
Background and rationale: Adolescence is a critical time of psychological and biological change, and advocacy has increased to identify interventions that protect against sexual and reproductive health (SRH) harms, which are disproportionately high among adolescent girls in sub-Saharan Africa. In much of eastern and southern Africa including western Kenya, where unprotected transactional sex is common, young females are highly vulnerable to sexually transmitted infections (STIs), including HIV, and pregnancy resulting in school dropout. While the burden of young female SRH harms is high for individuals, communities and health services, sustainable preventive interventions are lacking. Evidence of a positive association between girls' education, health and economic potential has strengthened international resolve to improve educational opportunities for adolescent girls. While SRH education has minimal impact on SRH harms, staying in school has shown to protect girls against early marriage, teen pregnancy, and HIV infection, with schoolgirls reporting less frequent sex, and fewer partners with less age disparity. While MDGs focused on primary school attendance, the post-2015 Sustainability Development Goals continue to encourage investment in secondary, tertiary and vocational education to build human capital, innovation and economic growth, but require the support of cost-effective interventions. Interventions using cash transfer (CT) have demonstrated a protective effect on girls SRH (HIV, HSV-2, sexual behaviours, and school indicators). Menstrual hygiene management (MHM) is a pervasive problem across low middle income countries (LMICs) and a lack of MHM materials and facilities negatively impact girls' school-life. This increases girls' vulnerability to coercive sex, which often creates a pathway to obtain necessities such as soap, sanitary products, and underwear; 10% of 15 year old girls report that they obtain money through sex to purchase sanitary products in western Kenya. To tackle these challenges, our team ran a pilot menstrual study in western Kenya. It provided MHM tools to adolescent girls in the form of reusable menstrual cups and disposable sanitary pads. The results demonstrated a lower prevalence of STI and bacterial vaginosis among girls who were provided with a single menstrual cup (one cup can last up to 10 years), and a lower prevalence of school dropout after 12 months follow-up compared to controls. This pilot requires replication in a larger trial population with longer follow-up. Comparison against CT offers an opportunity to examine the efficacy and cost-effectiveness of these different approaches to improve girls' life-chances in rural western Kenya. The study is designed to inform evidence-based policy to improve girls' health, school equity and their life-chances.
Primary objective: To determine the impact of menstrual cups alone, cash transfer alone, or the two in combination, in secondary schoolgirls on a composite of deleterious outcomes (HIV, HSV-2 infection, or school dropout).
Hypothesis: The investigators postulate the interventions tested will break the cycle of sexual and reproductive ill-health, under-achievement, and poverty which impede girls' successful completion of school.
Overview Study Design: Single site open-label 4-arm, school-cluster randomised controlled superiority trial. Schools are the unit of randomisation (clusters), with girls the unit of measurement. Schools will be randomly allocated into 4 arms using a 1:1:1:1 ratio and permuted block randomisation to minimise bias. Enrollment will be staggered over >=2 school terms if logistically required. Girls will be followed-up through graduation and into employment or up to 10 academic terms to determine if they complete secondary school (Form 4). Sealed, opaque envelopes will be prepared with the study allocation. Counsellors conducting HIV and HSV-2 testing, and laboratory technicians will be blinded to the study arm. Field staff who conduct home visits to confirm dropout will also be masked where feasible.
Sites: The study will be conducted in Siaya County, western Kenya. Depending on the recruitment rate enrolment will be expanded to other neighbouring counties.
Study Population: Secondary schoolgirls who attend eligible schools in the western Kenya study site. Girls will be residents of the area, with a history of established menses (>=3 times), no disability preventing participation, with parent or guardian's consent and girl's assent. Girls attending boarding schools or with visible/declared pregnancy will be excluded at baseline.
Study Interventions: 1. One menstrual cup (Mooncup®) with handwash soap termly; 2. Cash transfer (CT; girls' pocket money) via local community/mobile banking with financial literacy; 3. A combination of cup and CT interventions; 4. 'Usual practice' (control) with handwash soap termly.
Outcome Measures: Primary efficacy outcome: Composite endpoint comprised of incident HIV, HSV-2, and all-cause school dropout, by end of follow-up. Key secondary outcomes include incident HIV, HSV-2, school dropout, BV and reported sexual behaviours including pregnancy, quality of life measures, school indicators (performance, grade repitition, re-enrolment, absence, transfers), and cost-effectiveness. Primary safety outcome measure: toxic shock syndrome (TSS), and severe violence associated with intervention. Key secondary safety outcome include contamination on menstrual cups and other emergent harms associated with the interventions.
Follow-up procedures: HIV and HSV-2 serostatus will be assessed at baseline and around the time of final school term (Form 4), with interim testing or annual testing if funding allows, including for bacterial vaginosis and other STI. School dropout will be assessed every term until the end of Form (class) 4. Other endpoints will be evaluated at baseline, midline, and end of study. Safety monitoring of TSS and physical violence will be conducted throughout by study nurses, supplemented by health facilities and evaluation of HDSS census mortality data.
Sample size: Main trial: 84 schools (clusters) (21 per arm) with an approximate average of 46 girls per school (~3864 participants, 966 per arm). Protocol amendment v7: 96 schools with approximately 41.5 girls per school (3980 participants, 995 per arm).
Data Analysis: Primary trial analyses will be based on the intention to treat principle and a secondary analyses will also be done on the per protocol population. Generalised estimating equation (GEE) log binomial models will be used to analyse the primary endpoint and its components. The GEE model will include the arm as a fixed effect and school as a cluster effect. The RR values for the 5 pre-specified primary comparisons together with their 95% confidence intervals will be derived from the GEE model. The secondary endpoints will be analysed similarly using GEE models. For GEE analysis of a continuous endpoint such as quality of life, normal distribution and identity link functions will be used. For GEE analysis of a binary outcome (such as having an event of STI, HIV, pregnancy, or school dropout), binomial distribution and log link functions will be used; for GEE analysis of recurrence of events (such as number of sexual partners during a specific time), Poisson distribution and log link functions will be used. Covariate adjusted analysis of primary endpoint will be performed within the GEE framework with treatment as the study variable, and other predictors as covariates, and school as cluster effect. For qualitative analysis, FGD recordings will be transcribed verbatim with back translation. Transcripts will analysed using thematic analysis by study group, 2 researchers will separately assign codes for emergent themes, subthemes patterns, and associations using NVIVO with intercoder reliability checked and consensus reached following discussion. As themes emerge, differences and similarities will be compared across trial arms, and between study groups. Qualitative data from in depth interviews will be similarly evaluated. Protocol amendment v10:Secondary analysis on primary and secondary outcomes using 'at the margins' factorial analysis will also be conducted.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Siaya County
-
Siaya, Siaya County, Kenya, 40600
- 84 rural secondary schools in Siaya County (expanded to total 96 schools; Protocol v7)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Attend secondary day schools in the study area
- Resident of the study area
- Have a history of established menses (>=3 times)
- Have no disability preventing participation
- Have received parent or guardian's consent and themselves assent
Exclusion Criteria:
- Attend boarding schools
- Visibly pregnant or declare pregnancy at baseline (non-declared girls who are pregnant will be excluded from analysis after normal (or otherwise) delivery dates confirm pregnancy started prior to intervention)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Menstrual Cup
One menstrual cup (Mooncup®), an insertable menstrual hygiene product, together with handwash soap termly; puberty and hygiene education and cup training given at intervention.
|
Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect ~30 ml of menstrual blood when inserted into the vaginal canal
Other Names:
|
EXPERIMENTAL: Cash Transfer
Cash transfer (CT; girls' pocket money; of Ksh 1500 per term) via local community/mobile banking with financial literacy, puberty and hygiene education and cash pocket money financial literacy training given at intervention.
|
A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank.
Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.
Other Names:
|
EXPERIMENTAL: Cups and Cash
A combination of cup and cash transfer interventions; puberty and hygiene education, cup training, and cash pocket money financial literacy training given at intervention.
|
Combination of both interventions, using the same interventions and implementation methods.
Other Names:
|
NO_INTERVENTION: Control
'Usual practice' (control) with handwash soap termly; puberty and hygiene education given at intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite HIV, HSV-2, and school dropout
Time Frame: Form 4 (3 years)
|
The primary composite endpoint will include all three components (HIV+, HSV-2, school dropout) in girls sero-negative for both HIV and HSV-2 on enrolment and in girls where sero-status could not be determined on enrolment; i.e.among HIV-negative girls who were HSV-2 positive on enrolment only incident HIV infection and school dropout contribute to the primary endpoint.
|
Form 4 (3 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
School dropout
Time Frame: Form 4 (3 years)
|
Disaggregate of composite.
Participant does not attend school consecutively for at least one full term or longer.
Girls who attended part of Form (class) 4, but do not sit the final national Kenya Secondary Certificate of Education (KSCE) exams that year will be considered dropouts in that final term.
Investigators will evaluate reasons for dropout.
|
Form 4 (3 years)
|
HSV-2
Time Frame: Form 4 (3 years)
|
Disaggregate of composite.
HSV-2 incidence measured at end survey among girls sero-negative for HSV-2 on enrollment and in girls where sero-status could not be determined on enrollment.
|
Form 4 (3 years)
|
HIV
Time Frame: Form 4 (3 years)
|
Disaggregate of composite.
HIV incidence measured at end survey among girls sero-negative for HIV on enrollment and in girls where sero-status could not be determined on enrollment.
|
Form 4 (3 years)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reported sexual behaviour: age of debut
Time Frame: Form 4 (3 years)
|
Age of sexual debut, reported by participant at survey.
|
Form 4 (3 years)
|
Reported sexual behaviour: number of sexual partners
Time Frame: Form 4 (3 years)
|
Number of lifetime sexual partners, reported by participant at survey.
|
Form 4 (3 years)
|
Reported sexual behaviour: partner age concordance
Time Frame: Form 4 (3 years)
|
Age of partners, reported by participant at survey.
|
Form 4 (3 years)
|
Reported sexual behaviour: pregnancy
Time Frame: Form 4 (3 years)
|
Frequency of pregnancy, reported by participants at survey and validation among dropouts by study staff home visit.
|
Form 4 (3 years)
|
Reported sexual behaviour: contraceptive use
Time Frame: Form 4 (3 years)
|
Use of modern contraceptives, reported by participants at survey.
|
Form 4 (3 years)
|
Reported sexual behaviour: coercive sex
Time Frame: Form 4 (3 years)
|
Frequency of coercive sex, reported by participants at survey.
|
Form 4 (3 years)
|
School indicators: performance
Time Frame: Form 4 (3 years)
|
Participant grades from the Kenyan Certificate of Secondary Education Examinations (Form 4).
|
Form 4 (3 years)
|
School indicators: grade repitition
Time Frame: Form 4 (3 years)
|
Documented school year of participants by endline.
|
Form 4 (3 years)
|
School indicators: re-enrolment
Time Frame: Form 4 (3 years)
|
Frequency of participants re-enrolled after dropout by endline.
|
Form 4 (3 years)
|
School indicators: absence
Time Frame: Form 4 (3 years)
|
Frequency of absence, as documented in school registers.
|
Form 4 (3 years)
|
Pediatric quality of Life (PEDSQL)
Time Frame: Form 4 (3 years)
|
PEDSQL-23 measures 23 individual items to group participants' wellbeing into four categories: physical, emotional, social, and school wellbeing.
|
Form 4 (3 years)
|
EuroQual Quality of Life (Eq-5D)
Time Frame: Form 4 (3 years)
|
Eq-5D Evaluates participants health state in 5 dimensions, of mobility, self care, usual activities, pain/discomfort, anxiety/depression.
|
Form 4 (3 years)
|
Cost-effectiveness
Time Frame: Form 4 (3 years)
|
Estimate the societal cost consequences and the societal cost-effectiveness of the intervention packages, including the health services perspective, as compared to the controls.
|
Form 4 (3 years)
|
Other sexually transmitted infections
Time Frame: Form 4 (3 years)
|
Prevalence of other sexually transmitted infections including bacterial vaginosis, by end study (if funding permits).
|
Form 4 (3 years)
|
Primary safety outcome: toxic shock syndrome associated with interventions
Time Frame: Form 4 (3 years)
|
Toxic shock syndrome verified through safety monitoring by study nurses, associated with interventions
|
Form 4 (3 years)
|
Primary safety outcome: severe violence associated with interventions
Time Frame: Form 4 (3 years)
|
Severe violence verified through safety monitoring by study nurses, associated with interventions
|
Form 4 (3 years)
|
Secondary safety outcome: cup contamination
Time Frame: Form 4 (3 years)
|
Frequency of contamination of cups with e. coli among a random sample of used menstrual cups at intervals (~6 monthly) over the intervention trial
|
Form 4 (3 years)
|
Secondary safety outcome: other emergent harms associated with interventions
Time Frame: Form 4 (3 years)
|
Other unexpected emergent harms associated with interventions identified during safety monitoring
|
Form 4 (3 years)
|
School indicators: transfers
Time Frame: Form 4 (3 years)
|
Frequency of transfer to another school, as documented at follow-up
|
Form 4 (3 years)
|
Wellbeing-mental health:PHQ-9
Time Frame: Form 4 (3 years)
|
Anxiety-depression score using PHQ-9
|
Form 4 (3 years)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Penelope A Phillip-Howard, PhD, Liverpool School of Tropical Medicine
- Principal Investigator: Daniel Kwaro, MD, Kenya Medical Research Institute
Publications and helpful links
General Publications
- Zulaika G, Kwaro D, Nyothach E, Wang D, Zielinski-Gutierrez E, Mason L, Eleveld A, Chen T, Kerubo E, van Eijk A, Pace C, Obor D, Juma J, Oyaro B, Niessen L, Bigogo G, Ngere I, Henry C, Majiwa M, Onyango CO, Ter Kuile FO, Phillips-Howard PA. Menstrual cups and cash transfer to reduce sexual and reproductive harm and school dropout in adolescent schoolgirls: study protocol of a cluster-randomised controlled trial in western Kenya. BMC Public Health. 2019 Oct 21;19(1):1317. doi: 10.1186/s12889-019-7594-3.
- Zulaika G, Bulbarelli M, Nyothach E, van Eijk A, Mason L, Fwaya E, Obor D, Kwaro D, Wang D, Mehta SD, Phillips-Howard PA. Impact of COVID-19 lockdowns on adolescent pregnancy and school dropout among secondary schoolgirls in Kenya. BMJ Glob Health. 2022 Jan;7(1):e007666. doi: 10.1136/bmjgh-2021-007666.
- Zulaika G, Nyothach E, van Eijk AM, Obor D, Mason L, Wang D, Chen T, Kerubo E, Opollo V, Ngere I, Omondi Owino S, Oyaro B, Ter Kuile FO, Kwaro D, Phillips-Howard P. Factors associated with the prevalence of HIV, HSV-2, pregnancy, and reported sexual activity among adolescent girls in rural western Kenya: A cross-sectional analysis of baseline data in a cluster randomized controlled trial. PLoS Med. 2021 Sep 28;18(9):e1003756. doi: 10.1371/journal.pmed.1003756. eCollection 2021 Sep.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Menstrual Cup
-
Procter and GambleCompleted
-
University of Ghana Medical SchoolNYU Langone Health; Korle-Bu Teaching Hospital, Accra, Ghana; New York University...UnknownVaginal Fistula | Vesico Vaginal Fistula | Obstetric; InjuryGhana
-
University of Colorado, DenverRecruitingMenstrual Cup | IUD; Complications, MechanicalUnited States
-
Rush University Medical CenterNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingBacterial Vaginosis | Trichomonas Vaginitis | Neisseria Gonorrheae Infection | Chlamydia Trachomatis Infection | Vaginal MicrobiomeUnited States, Kenya
-
St George's, University of LondonUnknownGroup B StreptococcusUnited Kingdom
-
Stanford UniversityEnrolling by invitationHPV - Anogenital Human Papilloma Virus InfectionUnited States
-
University of California, San FranciscoEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingFistula | Obstetric Fistula | Fistula, Urinary | Fistula, VaginalGhana
-
Oslo University HospitalUniversity of OsloCompleted
-
Sahlgrenska University Hospital, SwedenCompletedProsthesis LooseningSweden
-
University of GuelphAgriculture and Agri-Food Canada; Saskatchewan Pulse GrowersCompleted